TEM-based Study of the Phenotype of Astrocytes Differentiated from Induced Pluripotent Stem Cells from a Healthy Donor and a Patient with Parkinson’s Disease

The aim of this study was to study the role of transmission electron microscopy (TEM) in assessment of the phenotype of astrocytes obtained with the directed differentiation technique from induced pluripotent stem cells (iPSCs) from a healthy donor and from a patient with a hereditary form of Parkinson’s disease (PD).

Materials and Methods. Monolayer astrocyte cultures differentiated from iPSCs from a healthy donor and a PD patient having the G2019S mutation in the LRRK2 gene were used in the study. The obtained glial cultures were characterized using real-time PCR and immunocytochemical staining for glia-specific genes and proteins. TEM was used to examine astrocyte ultrastructure.

Results. PCR analysis and immunocytochemical staining demonstrated that cell lines received from a healthy donor and a PD patient expressed the required pattern of glia-specific genes and synthesized astrocyte-specific proteins. However, some glia-specific genes were expressed at reduced levels by mutant cells. One of the most typical ultrastructural features of astrocytes received from iPSCs from a PD patient was destructive changes in mitochondria, including mitochondrial clearing, swelling, and cristae destruction. In many cells, mitochondria were completely absent after a long culturing. Another characteristic feature of cells with a mutation in the LRRK2 gene was the accumulation of vacuoles with contents of varied electron density. Distinct changes in the ultrastructure of nuclei, protein-synthesizing organelles, and cytoskeletal elements were also seen in cultured astrocytes with a PD-associated LRRK2 mutation. Here, the morphometric study did not reveal any differences in the average cell area, nuclear area, cytoplasm area, or nuclear-cytoplasmic ratio between astrocytes of the control line and the PD mutation line.

Conclusion. Reprogramming and obtaining of astrocytes from iPSCs received from a donor with a PD-associated mutation in the LRRK2 gene allow to assess the nature and dynamics of pathological morphochemical and ultrastructural changes caused by the mutation during gliogenesis. The use of combined techniques (PCR, immunocytochemistry, TEM) to compare cell cultures differentiated from iPSCs allow to assess, on the one hand, general culture parameters, such as the dynamics of culture differentiation based on changes in the expression level of specific genes and immunocytochemical markers, and on the other hand, morphofunctional changes at the level of individual cells. TEM demonstrates significant potential for studying cell cultures differentiated from iPSCs. This technique is instrumental for phenotyping the resulting cells based on their ultrastructure, assessing the degree of their morphological maturity, and identifying minor ultrastructural changes in cells, both pathological and differentiation-associated. The results of this TEM-based study indicate a pronounced decrease in mitochondrial viability and other ultrastructural abnormalities, thus confirming the idea of a significant role of astroglia in the development of the neurodegenerative process in the LRRK2-associated PD; hence, astroglia can be a basis for development of new approaches as well as for searching pharmacological targets in the pathogenetic therapy of the disease.

1. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18(R1): R48–R59, https://doi.org/10.1093/hmg/ddp012.
2. Trevisan L., Gaudio A., Monfrini E., Avanzino L., Di Fonzo A., Mandich P. Genetics in Parkinson's disease, state-of-the-art and future perspectives. Br Med Bull 2024; 149(1): 60–71, https://doi.org/10.1093/bmb/ldad035.
3. Paisán-Ruíz C., Jain S., Evans E.W., Gilks W.P., Simón J., van der Brug M., López de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Martí Carrera I., Pena A.S., de Silva R., Lees A., Martí-Massó J.F., Pérez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44(4): 595–600, https://doi.org/10.1016/j.neuron.2004.10.023.
4. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44(4): 601–607, https://doi.org/10.1016/j.neuron.2004.11.005.
5. Chen C., Soto G., Dumrongprechachan V., Bannon N., Kang S., Kozorovitskiy Y., Parisiadou L. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations. Elife 2020; 9: e58997, https://doi.org/10.7554/eLife.58997.
6. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006; 52(4): 587–593, https://doi.org/10.1016/j.neuron.2006.10.008.
7. Plowey E.D., Cherra S.J. 3rd, Liu Y.J., Chu C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 2008; 105(3): 1048–1056, https://doi.org/10.1111/j.1471-4159.2008.05217.x.
8. Friedman L.G., Lachenmayer M.L., Wang J., He L., Poulose S.M., Komatsu M., Holstein G.R., Yue Z. Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain. J Neurosci 2012; 32(22): 7585–7593, https://doi.org/10.1523/JNEUROSCI.5809-11.2012.
9. Gómez-Suaga P., Luzón-Toro B., Churamani D., Zhang L., Bloor-Young D., Patel S., Woodman P.G., Churchill G.C., Hilfiker S. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet 2012; 21(3): 511–525, https://doi.org/10.1093/hmg/ddr481.
10. Ramonet D., Daher J.P., Lin B.M., Stafa K., Kim J., Banerjee R., Westerlund M., Pletnikova O., Glauser L., Yang L., Liu Y., Swing D.A., Beal M.F., Troncoso J.C., McCaffery J.M., Jenkins N.A., Copeland N.G., Galter D., Thomas B., Lee M.K., Dawson T.M., Dawson V.L., Moore D.J. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011; 6(4): e18568, https://doi.org/10.1371/journal.pone.0018568.
11. Alegre-Abarrategui J., Christian H., Lufino M.M., Mutihac R., Venda L.L., Ansorge O., Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 2009; 18(21): 4022–4034, https://doi.org/10.1093/hmg/ddp346.
12. Streubel-Gallasch L., Giusti V., Sandre M., Tessari I., Plotegher N., Giusto E., Masato A., Iovino L., Battisti I., Arrigoni G., Shimshek D., Greggio E., Tremblay M.E., Bubacco L., Erlandsson A., Civiero L. Parkinson's disease-associated LRRK2 interferes with astrocyte-mediated alpha-synuclein clearance. Mol Neurobiol 2021; 58(7): 3119–3140, https://doi.org/10.1007/s12035-021-02327-8.
13. Miyazaki I., Asanuma M. Neuron-astrocyte interactions in Parkinson's disease. Cells 2020; 9(12): 2623, https://doi.org/10.3390/cells9122623.
14. Novosadova E.V., Arsenyeva E.L., Antonov S.A., Kazantseva E.A., Novosadova L.V., Kurko O.D., Illarioshkin S.N., Tarantul V.Z., Grivennikov I.A. Generation and characteristics of glial cellsfrom induced human pluripotent stem cells. Nejrohimiya 2020; 37(4): 358–367, https://doi.org/10.31857/S1027813320040068.
15. Soubannier V., Maussion G., Chaineau M., Sigutova V., Rouleau G., Durcan T.M., Stifani S. Characterization of human iPSC-derived astrocytes with potential for disease modeling and drug discovery. Neurosci Lett 2020; 731: 135028, https://doi.org/10.1016/j.neulet.2020.135028.
16. de Rus Jacquet A., Tancredi J.L., Lemire A.L., DeSantis M.C., Li W.P., O'Shea E.K. The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease. Elife 2021; 10: e73062, https://doi.org/10.7554/eLife.73062.
17. di Domenico A., Carola G., Calatayud C., Pons-Espinal M., Muñoz J.P., Richaud-Patin Y., Fernandez-Carasa I., Gut M., Faella A., Parameswaran J., Soriano J., Ferrer I., Tolosa E., Zorzano A., Cuervo A.M., Raya A., Consiglio A. Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson's disease. Stem Cell Reports 2019; 12(2): 213–229, https://doi.org/10.1016/j.stemcr.2018.12.011.
18. Novosadova E.V., Nekrasov E.D., Chestkov I.V., Surdina A.V., Vasina E.M., Bogomazova A.N., Manuilova E.S., Arsenyeva E.L., Simonova V.V., Konovalova E.V., Fedotova E. Yu., Abramycheva N.Yu., Khaspekov L.G., Grivennikov I.A., Tarantul V.Z., Kiselev S.L., Illarioshkin S.N. A platform for studying molecular and cellular mechanisms of Parkinson’s disease based on human induced pluripotent stem cells. Sovremennye tehnologii v medicine 2016; 8(4): 157, https://doi.org/10.17691/stm2016.8.4.20.
19. Lundin A., Delsing L., Clausen M., Ricchiuto P., Sanchez J., Sabirsh A., Ding M., Synnergren J., Zetterberg H., Brolén G., Hicks R., Herland A., Falk A. Human iPS-derived astroglia from a stable neural precursor state show improved functionality compared with conventional astrocytic models. Stem Cell Reports 2018; 10(3): 1030–1045, https://doi.org/10.1016/j.stemcr.2018.01.021.
20. Nahirney P.C., Tremblay M.E. Brain ultrastructure: putting the pieces together. Front Cell Dev Biol 2021; 9: 629503, https://doi.org/10.3389/fcell.2021.629503.
21. Ramos-Gonzalez P., Mato S., Chara J.C., Verkhratsky A., Matute C., Cavaliere F. Astrocytic atrophy as a pathological feature of Parkinson's disease with LRRK2 mutation. NPJ Parkinsons Dis 2021; 7(1): 31, https://doi.org/10.1038/s41531-021-00175-w.
22. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005; 102(51): 18676–18681, https://doi.org/10.1073/pnas.0508052102.
23. Bak L.K., Walls A.B., Schousboe A., Waagepetersen H.S. Astrocytic glycogen metabolism in the healthy and diseased brain. J Biol Chem 2018; 293(19): 7108–7116, https://doi.org/10.1074/jbc.R117.803239.
24. Vetchinova A.S., Kapkaeva M.R., Ivanov M.V., Kutukova K.A., Mudzhiri N.M., Frumkina L.E., Brydun A.V., Sukhorukov V.S., Illarioshkin S.N. Mitochondrial dysfunction in dopaminergic neurons derived from patients with LRRK2- and SNCA-associated genetic forms of Parkinson's disease. Curr Issues Mol Biol 2023; 45(10): 8395–8411, https://doi.org/10.3390/cimb45100529.
25. Singh A., Zhi L., Zhang H. LRRK2 and mitochondria: recent advances and current views. Brain Res 2019; 1702: 96–104, https://doi.org/10.1016/j.brainres.2018.06.010.
26. Cherra S.J. 3rd, Steer E., Gusdon A.M., Kiselyov K., Chu C.T. Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol 2013; 182(2): 474–484, https://doi.org/10.1016/j.ajpath.2012.10.027.
27. Lee J.H., Han J.H., Kim H., Park S.M., Joe E.H., Jou I. Parkinson's disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes. Acta Neuropathol Commun 2019; 7(1): 68, https://doi.org/10.1186/s40478-019-0716-4.
28. Matuz-Mares D., González-Andrade M., Araiza-Villanueva M.G., Vilchis-Landeros M.M., Vázquez-Meza H. Mitochondrial calcium: effects of its imbalance in disease. Antioxidants (Basel) 2022; 11(5): 801, https://doi.org/10.3390/antiox11050801.
29. Higgins C.M., Jung C., Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 2003; 4: 16, https://doi.org/10.1186/1471-2202-4-16.
30. Chaanine A.H. Morphological stages of mitochondrial vacuolar degeneration in phenylephrine-stressed cardiac myocytes and in animal models and human heart failure. Medicina (Kaunas) 2019; 55(6): 239, https://doi.org/10.3390/medicina55060239.
31. Lee S.J., Zhang J., Choi A.M., Kim H.P. Mitochondrial dysfunction induces formation of lipid droplets as a generalized response to stress. Oxid Med Cell Longev 2013; 2013: 327167, https://doi.org/10.1155/2013/327167.
32. Sánchez-Danés A., Richaud-Patin Y., Carballo-Carbajal I., Jiménez-Delgado S., Caig C., Mora S., Di Guglielmo C., Ezquerra M., Patel B., Giralt A., Canals J.M., Memo M., Alberch J., López-Barneo J., Vila M., Cuervo A.M., Tolosa E., Consiglio A., Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 2012; 4(5): 380–395, https://doi.org/10.1002/emmm.201200215.
33. Liu L., Zhang K., Sandoval H., Yamamoto S., Jaiswal M., Sanz E., Li Z., Hui J., Graham B.H., Quintana A., Bellen H.J. Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 2015; 160(1–2): 177–190, https://doi.org/10.1016/j.cell.2014.12.019.
34. Mallick K., Paul S., Banerjee S., Banerjee S. Lipid droplets and neurodegeneration. Neuroscience 2024; 549: 13–23, https://doi.org/10.1016/j.neuroscience.2024.04.014.
35. Galper J., Kim W.S., Dzamko N. LRRK2 and lipid pathways: implications for Parkinson's disease. Biomolecules 2022; 12(11): 1597, https://doi.org/10.3390/biom12111597.

Kutukova K.A., Ivanov M.V., Novosadova E.V., Brydun A.V., Arsenyeva E.L., Novosadova L.V., Kokorev I.V., Grivennikov I.A., Sukhorukov V.S., Illarioshkin S.N. TEM-based Study of the Phenotype of Astrocytes Differentiated from Induced Pluripotent Stem Cells from a Healthy Donor and a Patient with Parkinson’s Disease. Sovremennye tehnologii v medicine 2026; 18(1): 5, https://doi.org/10.17691/stm2026.18.1.01